CEO Dr John Lambert discusses the Amplia Therapeutics' (ASX: ATX) exciting progress in developing new experimental drugs to treat cancer and fibrosis, an update on the AMP945 clinical trial and the company's collaboration with the Garvan Institute.

Amplia Therapeutics (ASX: ATX) is an Australian pharmaceutical company developing new drugs for cancer and fibrosis.

Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.

Accurate time of recording, 21 October 2020 at 12pm AEDT.